About Donnatal

Donnatal Extentabs have been used successfully as adjunctive therapy for Irritable Bowel Syndrome for nearly 30 years.

An Extended History of Trust

PBM Pharmaceuticals acquired the rights to Donnatal Extentabs from Wyeth Laboratories in 2001. Following the acquisition, the response from the medical community and IBS patients for Donnatal Extentabs was overwhelming.

Both physicians and patients contacted PBM, expressing their appreciation for maintaining Donnatal Extentabs in the marketplace.

All Day, All Night... Donnatal Extentabs

Donnatal Extentabs are an extended release, combination antispasmodic therapy with a long history of trust:

• More than 2 million prescriptions filled in this category per year since 1991. ¹
• 40,000 patient days of this type therapy prescribed per year since 1991. ²
• Extensive documented long-term patient safety record. ³
• Trusted adjunct therapy by gastroenterologists and other physicians for nearly 30 years. ⁴

The Benefits of Extended Release

Donnatal Extentabs recommended dosing is twice daily, one Extentab tablet in the morning and one at night. A 12-hour dosing schedule is convenient for day and night.

The nighttime benefit afforded by extended release is important to the IBS sufferers whose symptoms occurring through the night prevent a full night's rest. Without proper rest at night, their quality of life is affected as well as their ability to be productive in school or in the workplace.

1.) Engstrom, PF, Goosenberg, EB. Diagnosis and Management of Bowel Diseases, First Edition, 1999; 2: 64.
2.) Data on file, PBM Pharmaceuticals, Inc.
3.) Data on file, PBM Pharmaceuticals, Inc.
4.) Data on file, PBM Pharmaceuticals, Inc.